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hospitalization with a respiratory infection or its potential complication, and all-cause mortality after
such hospitalization, adjusting for clinical and health care use variables. Cox and multi-state models
were applied for time-to-event analysis. RESULTS Of 343,505 included persons, 22.4% were vaccinated.
Vaccinated patients were on average older, had more morbidities, higher health care expenditures, and
had been more frequently hospitalized. In non-adjusted models, vaccination was associated with increased
risk of events. Adding covariates decreased the hazard ratio (HR) both for mortality and hospitalizations.
In the full model, the HR [95% confidence interval] for mortality during season was 0.82 [0.77-0.88], and
closer to null effect after season. In contrast, HR for hospitalizations was increased during season to 1.28
[1.15-1.42], with estimates closer to null effect after season. HR in multi-state models were similar to those
in the single-outcome models, with HR of mortality after hospitalization negative both during and after
season. CONCLUSION In patients with chronic diseases, influenza vaccination was associated with more
frequent specific hospitalizations, but decreased risk of mortality overall and after such hospitalization.
Our approach of iteratively considering PICO elements helped to consider various sources of bias in the
study sequentially. The selection of appropriate, specific outcomes makes the link between intervention
and outcome more plausible and can reduce the impact of confounding.
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a b s t r a c t
Background: Observational studies of influenza vaccination are criticized as flawed due to unmeasured
confounding. The goal of this cohort study was to explore the value and role of secondary claims data
to inform the effectiveness of influenza vaccination, while systematically trying to reduce potential bias.
Methods: We iteratively reviewed the components of the PICO approach to refine study design. We ana-
lyzed Swiss mandatory health insurance claims of adult patients with chronic diseases, for whom influ-
enza vaccination was recommended in 2014. Analyzed outcomes were all-cause mortality,
hospitalization with a respiratory infection or its potential complication, and all-cause mortality after
such hospitalization, adjusting for clinical and health care use variables. Cox and multi-state models were
applied for time-to-event analysis.
Results: Of 343,505 included persons, 22.4% were vaccinated. Vaccinated patients were on average older,
had more morbidities, higher health care expenditures, and had been more frequently hospitalized. In
non-adjusted models, vaccination was associated with increased risk of events. Adding covariates
decreased the hazard ratio (HR) both for mortality and hospitalizations. In the full model, the HR [95%
confidence interval] for mortality during season was 0.82 [0.77–0.88], and closer to null effect after sea-
son. In contrast, HR for hospitalizations was increased during season to 1.28 [1.15–1.42], with estimates
closer to null effect after season. HR in multi-state models were similar to those in the single-outcome
models, with HR of mortality after hospitalization negative both during and after season.
Conclusion: In patients with chronic diseases, influenza vaccination was associated with more frequent
specific hospitalizations, but decreased risk of mortality overall and after such hospitalization. Our
approach of iteratively considering PICO elements helped to consider various sources of bias in the study
sequentially. The selection of appropriate, specific outcomes makes the link between intervention and
outcome more plausible and can reduce the impact of confounding.
 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Vaccination is known to prevent influenza infections [1,2], and
some studies argue that it also attenuates their course and reduces
the need for intensive care treatment [3–5], prevents cardiovascu-
lar events [6,7] and respiratory complications [8]. However, the
magnitude of the total effect on subsequent health outcomes, hos-
pitalizations, mortality, and thus the overall impact on health is
https://doi.org/10.1016/j.vaccine.2020.06.019
0264-410X/ 2020 The Author(s). Published by Elsevier Ltd.
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debated, especially in older persons [9,10]. High-quality evidence
is lacking, particularly for outcomes such as mortality, because
randomized controlled trials (RCTs) are ethically questionable in
the populations of greatest interest [11]. It is argued that a genuine
uncertainty over the effect of the vaccination on mortality is not
present, and vaccination is already broadly recommended for per-
sonal and public health as part of standard care [12,13].
However, current ambiguity on the real-world effects of vacci-
nation potentially undermines its uptake and could even con-
tribute to vaccination coverage being low in many countries
worldwide [14–16]. Without precise quantification of the expected
effect, the potential benefit of vaccination-related public cam-
paigns and policies is also ambiguous.
1.1. Observational studies with administrative data
The lack of real-world RCTs makes observational studies based
on secondary data the next logical step. However, observational,
especially cohort, studies are sometimes criticized as systemati-
cally flawed due to unmeasured confounding [17–19]. The inability
to completely rule out inherent biases, particularly when unspeci-
fic outcomes are studied, has resulted in some recommendations
to avoid such studies altogether or to focus on test-negative design
[18,20].
Nevertheless, observational studies of secondary administrative
data can potentially contribute valuable information. Finding a
suitable application for them is especially attractive as such data
are readily available and could cover the whole population nation-
ally or regionally. With appropriate planning (study design) and
analysis strategy, observational studies can yield meaningful esti-
mates of effect size and inform the research questions of future
RCTs and other studies. Also, they could address outcomes that
are unfeasible to investigate with an RCT due to low event rates.
1.2. Research question and aims of the study
The goal of this study was to explore the value and role of sec-
ondary claims data to inform the effectiveness of influenza vacci-
nation in a systematic manner, thereby addressing recent
methodological debates. We aimed to achieve sufficient reduction
of threats to validity by carefully developing the study design
according to the basic elements of the PICO approach: the selection
of population, intervention, comparator group (control of con-
founding), and outcomes.
We compared the effect of vaccination on several health out-
comes of varying specificity for influenza (all-cause mortality,
specific hospitalizations with a respiratory infection or its potential
complication, and mortality after such hospitalizations). We were
the most interested in the attenuating effect of vaccination on sub-
sequent outcomes after an infection, such as mortality after
influenza-related hospitalization.
2. Methods
2.1. Study framework and research question
We explored how our broad research question could be speci-
fied and answered with administrative claims data and the poten-
tial biases reduced, by iteratively reviewing the components of the
PICO approach and refining study design (Fig. 1) [21,22]. PICO
approach is primarily used to formulate clinical questions [21],
but can also be employed as a strategy to focus a research question.
First, we considered the population – adult patients with chronic
diseases for whom The Swiss Federal Office of Public Health (FOPH)
recommends vaccination. We additionally analyzed the subgroup
of  65-years-old persons with chronic diseases (65 subgroup).
We hypothesized that the health status of older persons within this
population would be defined better, as more health services are
used, and thus, diagnoses are better captured in claims data.
Second, we defined intervention as vaccination occurring
between September 1 and December 31, 2014. In the models, we
included vaccination as a time-varying exposure. Misclassification
could not be avoided entirely, as some vaccination paid out-of-
pocket may not be captured in the claims data.
Third, to improve comparability of the vaccinated and non-
vaccinated groups, we controlled for potential confounding and
sequentially adjusted for (1) standard variables: age, sex, indica-
tors of major chronic diseases, and number of pharmaceutical costs
groups (PCG) in 2014, i.e., specific types of prescribed medications
used as markers of chronic conditions [23], (2) additional variables
of health care use and expenditure in the previous year (2013). The
variables are described in detail in the next section.
Fourth, we modelled all-cause mortality and specific hospital-
izations as outcomes. We included both outcomes in a multi-state
model to account for competing risks and investigate mortality
after hospitalization. We expected specific hospitalizations and
mortality after hospitalization to be more specific outcomes than
all-cause mortality.
Based on the refined research question, we formulated these
hypotheses: that influenza vaccination would be associated with
a smaller risk of mortality, specific hospitalization, and mortality
after such hospitalization; that the effect will be greater on specific
outcomes than all-cause mortality; and that the effect will be more
pronounced during than after influenza season. We also expected
Fig. 1. Iterative study improvement framework based on questions related to each element of PICO.
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the estimated effect to be more accurate in the  65 subgroup and
after adjusting for additional variables.
2.2. Dataset and population
We analyzed mandatory health insurance claims from the Hel-
sana Group, covering approximately 1.2 million people (15% of the
Swiss population). Basic mandatory health insurance in Switzer-
land is provided by several private companies, Helsana Group
being one of the largest.
The Swiss Federal Office of Public Health (FOPH) recommends
influenza vaccination for persons with increased risk for influenza
complications (such as  65-year-old persons, patients with
chronic diseases, pregnant women, and premature newborns)
and those regularly in contact with such persons or with occupa-
tional risk factors [13]. In this study, we included Helsana-
insured patients older than 18 years with a clinical indicator of
cardiovascular, respiratory, metabolic, neurologic, musculoskele-
tal, hepatic or renal disease or immune deficiency, as defined by
the FOPH recommendations [13], for whom vaccination would be
recommended. Indicators of these conditions were relevant PCG
in 2014 and hospitalizations with a relevant diagnosis in 2013.
Patients with incomplete insurance coverage in years 2014 or
2015, not surviving until September 1, 2014, receiving reimburse-
ment for outpatient services via lump-sums in 2014 (which com-
prises some patients living in nursing homes), asylum seekers,
those living outside Switzerland, and Helsana employees were
excluded.
2.3. Exposure (influenza vaccination), outcome and covariates
For included patients, we screened for influenza vaccination
claims (coded as J07BB02 with the Anatomical Therapeutic Chem-
ical Classification System (ATC) [24]) between September 1 to
December 31, 2014. A person was defined as immunized (effec-
tively vaccinated) after two weeks from the claim.
The beginning of the first specific hospitalization in each period
and death were recorded as outcome events. Specific hospitaliza-
tions were identified by relevant Swiss Diagnosis-Related Groups
codes (SwissDRG, reflecting jointly major inpatient diagnoses and
interventions [25], referred to as hospitalization further on), which
are detailed in the Supplementary Table 1a. The observation time
was divided into three periods: before (September 1 – December
14, 2014), during (December 15, 2014 – May 3, 2015) and after
(May 4 – August 31, 2015) the influenza season, based on the Euro-
pean Centre for Disease Prevention and Control (ECDC) report [26].
An illustrative timeline of exposure and outcomes is shown in
Fig. 2.
Additional explanatory variables were age, sex, number of PCG
in 2014, binary variables of major chronic diseases, and variables of
health care use and expenditure in 2013. Variables of major
chronic diseases included indicators for cardiovascular, respira-
tory, metabolic, neurologic, musculoskeletal, hepatic or renal dis-
ease or immune deficiency. Binary variables of health care use
were: (1) an indicator of any hospitalization for acute disease,
and (2) any stay in a nursing home. To reflect health care expendi-
ture, we used the residuals of the total reimbursed expenditure in
2013, after modelling it with the predictive model used for Swiss
risk equalization between health insurers [27]. This model uses
variables of sex, age, and comorbidities to predict the annual
health care expenditure. Thus, a positive residual could be an indi-
cator of poor health status, independent of these variables. As the
latter variables were included in the models as covariates sepa-
rately, residuals instead of the total expenditure were used to pre-
vent multicollinearity.
2.4. Sequence of data analysis
Baseline characteristics for non-vaccinated and vaccinated
patients (all and  65 subgroup) were calculated as percentages
for binary and means with standard deviation for continuous vari-
ables. Propensity models for vaccination were constructed but
eventually not used due to low sensitivity.
Separate Cox models were constructed for mortality and hospi-
talizations, for all patients and the  65 subgroup. The effect of
vaccination was stratified by time period. In addition, multi-state
models including both death and hospitalizations, and thus consid-
ering death after hospitalization, were run for all patients and
the  65 subgroup. One expected effect of vaccination was attenu-
ation of influenza infection and thus decreased mortality after
Fig. 2. Observation period, intervention (vaccination) and outcomes timeline, The observation period was between Sept 1, 2014, and Aug 31, 2015. It was divided into three
periods: before, during and after influenza season. Lines 1–5 represent example persons in the analyzed population. Dark blue represents vaccinated person-time (1,3,5).
Vertical lines with * represent hospitalizations, regarded as events that happen on the hospitalization date. Death within the same time period as a hospitalization is a
separate outcome in the multi-state model (4). The observation period ends on August 31, 2015 (1) or death, if earlier (2,3,4,5).
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hospitalization. Multi-state models can handle such multiple com-
peting endpoints in a time-to-event analysis, and help to discern
their interactions [28]. The analysis was done with R 3.6.0 [29].
The probability of vaccination is not constant through the before
influenza season. Vaccination utilization is usually low before
September, increases until mid-November and then decreases to
low again by the end of December. Therefore, the probability of
being vaccinated is not proportional to time in the before season.
Furthermore, the relationship between the risk of mortality and
propensity for vaccination might not be constant through the be-
fore season. In consequence, a person with high mortality risk
(i.e., terminally ill) might be disproportionally more likely to be
vaccinated if surviving until December, as compared to surviving
until October. For these reasons, we assumed that estimates of vac-
cination effect would not be accurate in the before season and ana-
lyzed only outcomes in the periods during and after influenza
season.
All procedures performed in the study were in accordance with
the ethical standards of the 1964 Helsinki declaration and its later
amendments. Study data were anonymized before analysis.
According to the national ethical and legal regulations, ethical
approval was not required for this type of retrospective study. This
was confirmed by a waiver of the competent ethics committee
(Kantonale Ethikkommission Zürich, dated January 11, 2017).
3. Results
Baseline characteristics of the study population are shown in
Table 1. Of 343,505 included persons, 22.4% were vaccinated, and
35.0% of 177,107 in the  65 subgroup. Vaccinated patients were
older on average, had more morbidities, higher health care expen-
ditures, and had been more frequently hospitalized for acute dis-
ease or stayed in a nursing home in the previous year.
Hazard ratios (HR) for vaccination effect on mortality and hos-
pitalizations during and after influenza season are shown in
Table 2. In non-adjusted models, vaccination was associated with
increased risks of events. Adjusted HR estimates for all patients
and the  65 subgroup were similar. Adding covariates decreased
HR both for mortality (away from null effect) and hospitalizations
(closer to null effect). In the full model, the HR [95% CI] for mortal-
ity during season was 0.82 [0.77–0.88] for all and 0.82 [0.77–0.88]
for the  65 subgroup. It was closer to null effect after season. In
contrast, HR for hospitalizations was greater than 1 during season,
with a wider confidence interval than for the mortality: 1.28
[1.15–1.42] for all and 1.22 [1.09–1.36] for the  65 subgroup.
The estimates after season were closer to null effect, with slightly
wider confidence intervals, overlapping HR of 1. Effect estimates of
the models are shown in full in Supplementary Table 2a.
HR in multi-state models were similar to those in the single-
outcome models (Table 3). HR of mortality after hospitalization
was below 1 for all and the  65 subgroup during and after season,
with wide confidence intervals overlapping HR of 1.
In a sensitivity analysis, a wider and a narrower definitions of
influenza season were applied, yielding similar estimates and con-
fidence interval bounds of the vaccination effect on mortality, hos-
pitalizations, and mortality after hospitalizations (details in
Supplementary Files 1a and 1b).
4. Discussion
In this study, influenza vaccination was associated with lower
mortality during as well as after the influenza season. During the
influenza season, we observed an increased risk of hospitalizations
with a respiratory infection or its potential complication for the
vaccinated persons. Despite this seemingly paradoxical effect,
multi-state models showed that mortality after such hospitaliza-
tions was decreased, hinting at a potentially attenuating effect of
vaccination. In other words, although vaccination may not prevent
all infections and hospitalizations, influenza seemed to be less fre-
quently fatal in chronically ill persons and those aged 65 years and
older, if vaccinated.
The observed vaccination coverage for patients with chronic
diseases was lower than estimated in other studies (22.4% in this
vs. 30% in a 2014 FOPH survey [30], and 23.4–42.5% for various
chronic diseases in the 2012 Swiss Health Survey (SHS) [31]). It
was more similar to other studies in the  65 subgroup (35.0% in
this vs. 29% in persons  65 years in the FOPH survey, and 43.4–
52.0% in the SHS). The reasons for low vaccination uptake in
Switzerland have been rarely studied in the general population.
In a survey of Swiss health care workers, reporting similarly low
vaccination rates, the most commonly stated reasons were fear
of short-term adverse effects, insufficient evidence of benefits,
and fear of restricted right for self-determination [32].
Reduction of mortality risk in vaccinated persons has been fre-
quently seen in other observational cohort studies, with widely
ranging effect estimates [18]. We believe that we were able to
Table 1
Baseline characteristics of chronically ill patients with recommended influenza vaccination in 2014.
All patients 65-year-old
Non-vaccinated Vaccinated Non-vaccinated Vaccinated
N (%) 266,588 (77.6) 76,917 (22.4) 115,071 (65.0) 62,036 (35.0)
Sex (female) (N (%)) 147,894 (55.5) 43,677 (56.8) 67,166 (58.4) 36,010 (58.0)
Age (mean (SD)) 60.52 (16.70) 73.59 (12.14) 75.74 (7.41) 78.12 (7.45)
Acute hospitalization(s) in 2013 (N (%)) 39,455 (14.8) 16,245 (21.1) 21,256 (18.5) 13,580 (21.9)
Nursing care in 2013 (N (%)) 5585 (2.1) 5379 (7.0) 5272 (4.6) 5162 (8.3)
High outpatient med. costs in 2013 (N (%)) 13,958 (5.2) 7325 (9.5) 5512 (4.8) 4637 (7.5)
Health care expenditure in 2013 (CHF, mean (SD)) 6460.22 (11677.13) 10395.50 (15203.85) 7624.47 (11861.20) 10106.99 (13813.64)
N of PCG (median (IQR)) 2.00 [1.00, 4.00] 3.00 [2.00, 5.00] 3.00 [2.00, 4.00] 4.00 [2.00, 5.00]
Specific PCG and inpatient diagnoses in 2014
Cardiovascular (%) 183,552 (68.9) 66,310 (86.2) 100,164 (87.0) 56,195 (90.6)
Cancer (%) 7497 (2.8) 2864 (3.7) 4060 (3.5) 2264 (3.6)
Diabetes (%) 33,445 (12.5) 14,944 (19.4) 17,408 (15.1) 11,742 (18.9)
Respiratory (%) 82,736 (31.0) 25,551 (33.2) 31,237 (27.1) 19,822 (32.0)
Immune-suppression (%) 75,949 (28.5) 22,497 (29.2) 26,942 (23.4) 16,861 (27.2)
Neurologic (%) 27,424 (10.3) 10,071 (13.1) 11,497 (10.0) 7886 (12.7)
Kidney/liver (%) 4896 (1.8) 2861 (3.7) 3820 (3.3) 2538 (4.1)
High outpatient medication costs in 2013 were defined as >5000 CHF. N – number, SD – standard deviation, med. – medication, CHF – Swiss Franc, PCG - pharmaceutical costs
groups, IQR – interquartile range.
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control for further confounders of health status than most studies
by considering additional proxies for it: health care use and expen-
diture variables. Few observational studies of influenza vaccine
effectiveness have adjusted for these variables before. For example,
Bellino et al. [33] found that health care expenditure was higher in
vaccinated patients, and had a significant effect in Poisson regres-
sion models of mortality and hospitalization. In our study,
although health care use and expenditure variables had a signifi-
cant effect in the survival models of mortality and hospitalizations,
adding them to the models had almost no impact on the estimated
vaccination effect (Table 2). This could be partly because health
care use and indicators of comorbidities (e.g., diagnoses) tend to
correlate in claims datasets [34], and thus health care use might
not add substantial explanatory information once the indicators
of comorbidities are already in the model.
Vaccination is usually associated with decreased risk for hospi-
talization [35]. The seemingly paradoxical increase observed in our
study could be due several reasons. First, it could reflect that vac-
cinated patients had a higher risk of becoming infected (e.g., expo-
sure in public spaces, work, or family) or suffer complications
requiring hospitalization (e.g. impaired immune system), which
was not captured by the available variables. Second, SwissDRG
codes used to define influenza-related hospitalizations might not
be specific enough. Some hospitalizations could have been related
to other infections instead – which would not be influenced by the
vaccination, but could be higher in the vaccinated group due to
comorbidities or other risk factors. Third, some hospitalizations
could be driven by patient or physician preferences, although we
deem this unlikely, as the selected SwissDRG codes reflect serious
medical conditions rather than elective treatments.
Although more hospitalizations were observed among vacci-
nated persons in our study, mortality afterward was lower. This
hints at a potential attenuating effect of influenza vaccination.
We did not find studies directly reporting such effect for vaccina-
tion. However, some indirect observations suggest possible expla-
nations. In a population-level study of specific hospitalizations and
subsequent mortality in Norway, Ruiz et al. [36] observed higher
influenza hospitalization rates but lower subsequent mortality
for patients with type 2 diabetes compared to non-diabetic
patients (although vaccination was associated with less frequent
hospitalization in both groups). Potentially, type 2 diabetes in the
Ruiz et al. study – and comorbidities not fully controlled for in vac-
cinated persons in our study – lead to lower hospital admission
thresholds and thus apparent increase in hospitalizations but not
worse subsequent mortality.
Decreased mortality and other severe outcomes, such as the
need for intensive care treatment, in vaccinated patients after
influenza-related hospitalizations have been observed in a variety
of age and patient groups [3,37–39], although not consistently so
[40,41]. Our study was different from most of those referenced
because we considered deaths not only immediately after hospital-
ization, but during the whole influenza season (or after season per-
iod). While the observed effect size was not statistically significant
in our study (Table 3), this may be due to a small number of events.
Our study was also different from those mentioned in that we
used a multi-state model for mortality and hospitalizations,
thereby considering the competing risks of these events. Compet-
ing risks pose a problem when any other outcome than mortality
is analyzed, particularly in older populations with high morbidity.
We found only one comparable study that considered death as a
competing risk for intensive care unit (ICU) admission and hospital
length of stay [3]. However, we did not find studies analyzing
death as a competing risk for influenza-related hospitalization.
While planning this study, we expected that the competing risk
of death could result in seemingly paradoxically increased
hospitalization risk in the vaccinated population. Although the
Table 2
Hazard ratio estimates for the effect of vaccination on mortality and hospitalization.
Mortality Hospitalization
Model covariates During season After season During season After season
All patients
Vaccination only 2.21 [2.07–2.35] 2.27 [2.10–2.44] 2.57 [2.33–2.83] 2.18 [1.90–2.51]
+ standard covariates 0.86 [0.81–0.92] 0.90 [0.83–0.98] 1.30 [1.17–1.44] 1.10 [0.96–1.27]
Full model 0.82 [0.77–0.88] 0.87 [0.80–0.94] 1.28 [1.15–1.42] 1.09 [0.94–1.25]
65-year-old
Vaccination only 1.30 [1.22–1.39] 1.33 [1.23–1.44] 1.64 [1.47–1.83] 1.40 [1.20–1.63]
+ standard covariates 0.86 [0.80–0.92] 0.88 [0.80–0.92] 1.23 [1.10–1.37] 1.04 [0.89–1.22]
Full model 0.82 [0.77–0.88] 0.85 [0.78–0.92] 1.22 [1.09–1.36] 1.03 [0.89–1.21]
* These models are fully specified in supplementary Table 2a. Only the first hospitalization in the specified season is considered. Standard covariates included age, sex,
indicators of major chronic diseases, and number of PCG. Full model included the standard covariates as well as indicators of health care use (hospitalization for acute disease,
stay in a nursing home) and expenditure in the previous year (residuals of the total reimbursed health care expenditure, as modelled with the current approach for Swiss risk
equalization between health insurers).
Table 3
Multi-state models: hazard ratio estimates for the effect of vaccination on hospitalization and death, and the number of observed events.
During season After season
D H H ? D D H H ? D
HR [95% CI]
All persons 0.79 [0.74–0.85] 1.25 [1.13–1.39] 0.79 [0.60–1.04] 0.91 [0.84–0.99] 1.13 [0.97–1.31] 0.79 [0.51–1.22]
65 0.80 [0.75–0.86] 1.21 [1.08–1.35] 0.86 [0.64–1.15] 0.88 [0.80–0.96] 1.05 [0.90–1.23] 0.65 [0.41–1.05]
N of events
All persons 3764 1655 255 2662 861 109
65 3407 1307 220 2341 659 88
HR – hazard ratio, CI – confidence interval, N- number, D – death, H – first hospitalization, H? D – death after hospitalization during specified period, all persons – all persons
with chronic diseases, included in the study, 65 – 65-year-old or older.
Multi-state models consider multiple competing outcomes (hospitalization and death) in the same model. Time periods of during and after season were modelled separately.
CI of HR in grey overlap 1.00. Patients that were hospitalized in a previous time period but died in the next one were denoted as H in the previous and as D in the next time
period (not H ? D), because partitioning of time periods creates an extra time interval between these events.
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paradoxical effect persisted, its size was slightly smaller (closer to
null effect) in the multi-state model (compare Tables 2 and 3).
In this study, we did not model the before season effect of
vaccination. Although null effect of vaccination before season is
argued to be essential as a check for residual confounding and
the validity of an observational study [9], this condition could
probably only be fulfilled in a randomized trial. Many observa-
tional studies comparing the effect of vaccination before, during
and after influenza season have found that the before season
effect is the highest, while the after season effect is often smaller
than during the influenza season [18]. Ultimately, different pop-
ulations are compared in these periods, as deceased persons do
not enter subsequent periods of analysis. Although using after
season instead of before season estimates does not avoid this
issue, analyzed patients in these periods at least have the same
temporal window to receive vaccination and be exposed to
influenza.
Observational cohort studies based on secondary administra-
tive data have been criticized in influenza effectiveness research
as not suitable for eliminating confounding and bias. We aimed
to improve the validity of our study by systematically and itera-
tively reviewing its design and focusing research question in an
effort to minimize bias. Explicit consideration of all the elements
of the PICO could be used to improve other observational studies
of influenza vaccination and beyond. The approach draws attention
to the selection of specific outcomes and to the comparability of
groups – a strategy similar, but not as explicit and structured as
specifying an emulated target trial [42]. In contrast, PICO approach
is not an independent study design strategy and does not provide
guarantees (e.g., of eliminating all confounding). Instead, it pro-
vides guidance for defining the research question that would be
meaningful and feasible to answer with a given data source.
4.1. Limitations
This study has several limitations. First, we cannot entirely rule
out residual confounding, given the use of secondary administra-
tive data. We controlled for PCG-assessed comorbidity, health care
use, and expenditure; however, these are imperfect proxies of indi-
viduals’ health status [34]. Further confounders such as pneumo-
coccal vaccination and the severity of measured comorbidities
could not be controlled for. Second, misclassification could be pre-
sent due to vaccination paid out-of-pocket. Vaccination provided
before the deductible is exceeded is not reimbursed; in case the
invoice is not automatically submitted to the health insurance, it
is not recorded in the claims-based dataset. However, we included
only people with chronic diseases, who are likely to exceed their
deductible, especially by the time window of vaccination
(September-December). Also, vaccination coverage in our study,
particularly in older persons, did not differ substantially from that
reported by other sources. Third, our dataset lacked outpatient
diagnostic and inpatient test information. Therefore, we could
not use even more specific outcomes, such as laboratory-
confirmed influenza infection. Fourth, as baseline covariates such
as chronic conditions and health care use were recorded once (at
the end of 2013), we could not adjust for time-varying
confounding.
Finally, a general caveat of influenza vaccination effectiveness
research is that the vaccine and prevalent virus match changes
every year. In 2014/2015, it was rather low [26]. The comparability
of results from different seasons is debatable. However, the pri-
mary aim of this study was not to precisely estimate the effect size
of a particular vaccine/virus match but to see if an attenuating
effect of vaccination could be gleaned from administrative claims
data in general.
5. Conclusions
In this study, influenza vaccination was associated with more
frequent specific hospitalizations, but decreased risk of mortality
overall and after such hospitalization in patients with chronic dis-
eases. Our approach of iteratively considering each PICO element
helped to consider various sources of bias in the study sequentially.
The selection of appropriate, specific outcomes makes the link
between intervention and outcome more plausible and can reduce
the impact of confounding. Administrative data and cohort studies
can be useful in influenza vaccine effectiveness research – if not for
estimating precise effect sizes, then at least for uncovering poten-
tial mechanisms of the effect in different populations. Further
studies with administrative data on vaccine effectiveness should
carefully consider the selection of outcome, population, and con-
founding variables, in order to achieve the best possible study
design.
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